scholarly journals The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis

2017 ◽  
Vol 1 (6) ◽  
pp. 524-537 ◽  
Author(s):  
Guillaume Wettstein ◽  
Jean-Michel Luccarini ◽  
Laurence Poekes ◽  
Patrick Faye ◽  
Francine Kupkowski ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Metabolic Disorders ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
New Generation

scholarly journals Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets

PPAR Research ◽  
2017 ◽  
Vol 2017 ◽  
pp. 1-13 ◽  
Author(s):  
Yadan Chen ◽  
Haiming Ma ◽  
Dasheng Zhu ◽  
Guowei Zhao ◽  
Lili Wang ◽  
...  
Keyword(s):  
Adenosine Monophosphate ◽  
Future Research ◽  
Diabetic Patients ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Downstream Effectors ◽  
Insulin Sensitizers ◽  
Mitochondrial Target ◽  
Unmet Demand ◽  
New Generation

Insulin resistance is the undisputed root cause of type 2 diabetes mellitus (T2DM). There is currently an unmet demand for safe and effective insulin sensitizers, owing to the restricted prescription or removal from market of certain approved insulin sensitizers, such as thiazolidinediones (TZDs), because of safety concerns. Effective insulin sensitizers without TZD-like side effects will therefore be invaluable to diabetic patients. The specific focus on peroxisome proliferator-activated receptorγ- (PPARγ-) based agents in the past decades may have impeded the search for novel and safer insulin sensitizers. This review discusses possible directions and promising strategies for future research and development of novel insulin sensitizers and describes the potential targets of these agents. Direct PPARγagonists, selective PPARγmodulators (sPPARγMs), PPARγ-sparing compounds (including ligands of the mitochondrial target of TZDs), agents that target the downstream effectors of PPARγ, along with agents, such as heat shock protein (HSP) inducers, 5′-adenosine monophosphate-activated protein kinase (AMPK) activators, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) selective inhibitors, biguanides, and chloroquines, which may be safer than traditional TZDs, have been described. This minireview thus aims to provide fresh perspectives for the development of a new generation of safe insulin sensitizers.

Mass spectrometry of doping preparations of a new generation: Peroxisome proliferator-activated receptor agonists

2010 ◽  
Vol 65 (13) ◽  
pp. 1411-1419
Author(s):  
M. A. Dikunets ◽  
E. D. Virus ◽  
E. N. Semenistaya ◽  
T. G. Sobolevsky ◽  
G. M. Rodchenkov
Keyword(s):  
Mass Spectrometry ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Receptor Agonists ◽  
New Generation

Peroxisome Proliferator-Activated Receptor-  Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats

Diabetes ◽  
1998 ◽  
Vol 47 (8) ◽  
pp. 1326-1334 ◽  
Author(s):  
R. E. Buckingham ◽  
K. A. Al-Barazanji ◽  
C. D. N. Toseland ◽  
M. Slaughter ◽  
S. C. Connor ◽  
...  
Keyword(s):  
Pancreatic Islet ◽  
Receptor Agonist ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor
Sign in / Sign up

Export Citation Format

Share Document